TASCENSO ODT® (fingolimod)

is not a generic

Green Tick

Unique ODT Formulation

Green Tick

Patient Support

Green Tick

Not Substitutable at Pharmacy Level

Green Tick

Every Batch Tested and Verified

Not a generic stamp

Enroll Your Patients in Just 4 Steps

  1. Download form
  2. Print the enrollment form
  3. Complete all required fields
  4. Either fax the form to Cycle Vita at + 1 (888) 385-8482 or email it to hello@cyclevita.life

That’s it! As soon as a completed enrollment form is sent to Cycle Vita, we can provide individualized support to your eligible* patients.

Download arrow down

Download enrollment form

Tascenso Dissolve Icon

Product

TASCENSO ODT is the same proven fingolimod you are familiar with, but it comes in a unique orally disintegrating tablet formulation.1

  • Unique orally disintegrating tablet for MS treatment
  • Same proven fingolimod
  • Same efficacy & safety as Gilenya®**
  • Not a generic²
  • Not substitutable at the pharmacy level²
  • Dissolves on the tongue in seconds
  • Once daily, with or without food, with or without water
  • Available as 0.25 mg and 0.5 mg orally disintegrating tablets
Find out more
Tascenso Care Icon

Support

We know that life-changing treatments need a support system which is tailored to the unique challenges your patients face. That’s why we created Cycle Vita, our dedicated hub support program, which delivers individualized product support* at every step. Including:

  • TASCENSO Time Program (in-home baseline assessments and first dose observation)
  • Financial assistance (including $0 co-pay)
  • Bridge Program
  • Medication Adherence Support
Find out more

Initiating Treatment

Switching to TASCENSO ODT

For patients currently taking the same dose (0.25 mg or 0.5 mg) of another fingolimod treatment a first dose observation (FDO) will not be required, providing the patient has not had a lapse in treatment for 14 days or more.1

Our priority is to ensure patients experience a smooth transition from their current disease modifying therapy to TASCENSO ODT.

Starting on TASCENSO ODT

Patients who are currently not on another fingolimod treatment or are increasing their fingolimod dose (from 0.25 mg to 0.5 mg) will need to have baseline assessments (BA) and a FDO to initiate therapy.1

Through the TASCENSO Time Program, eligible patients will have convenient access to in-home FDO and BAs as necessary to initiate their treatment. Our team has extensive experience in the management and delivery of FDO and BAs and is committed to supporting your patients during this process.

Cycle Pharma Logo

How to Enroll Your Patients

  1. Download Form
  2. Print the enrollment form
  3. Complete all required fields
  4. Either fax the form to Cycle Vita at + 1 (888) 385-8482 or email it to hello@cyclevita.life

That’s it! As soon as a completed enrollment form is sent to Cycle Vita, we can provide individualized support to your eligible* patients.

Download arrow down

Download enrollment form

References

1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.

2. FDA., 2023. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed April 25th 2023. Available: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

* Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.

** Gilenya® is a registered trademark of Novartis AG.